Amplitude's acquisition is a part of Zydus’ priority verticals in the medtech segment to build its global presence.
(Image used for representational purpose Photo Source freepik)
Zydus is adding growth levers in its medtech segment (cardiology, nephrology, orthopaedics). However, considering stable earnings over FY25-27, we maintain Neutral rating on the stock.